Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls Sells 54,702 Shares

Savara Inc (NASDAQ:SVRA - Get Free Report) CEO Matthew Pauls sold 54,702 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares of the company's stock, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Savara Price Performance

Shares of SVRA stock traded up $0.05 during midday trading on Monday, reaching $3.26. 846,141 shares of the company were exchanged, compared to its average volume of 1,276,285. The company's 50 day moving average price is $3.52 and its two-hundred day moving average price is $4.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The company has a market cap of $559.48 million, a P/E ratio of -7.47 and a beta of 0.92. Savara Inc has a 12 month low of $2.82 and a 12 month high of $5.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). On average, sell-side analysts expect that Savara Inc will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Evercore ISI reissued an "in-line" rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities reaffirmed a "market outperform" rating and set a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright decreased their price objective on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $10.17.

Institutional Trading of Savara

Several institutional investors have recently modified their holdings of SVRA. Vestal Point Capital LP raised its position in Savara by 24.7% in the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company's stock worth $34,302,000 after acquiring an additional 1,600,000 shares in the last quarter. Frazier Life Sciences Management L.P. grew its stake in shares of Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company's stock worth $32,874,000 after purchasing an additional 4,157,385 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company's stock worth $20,879,000 after purchasing an additional 3,443,541 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Savara by 54.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company's stock valued at $2,928,000 after purchasing an additional 242,249 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Savara by 34.5% during the second quarter. Affinity Asset Advisors LLC now owns 1,546,850 shares of the company's stock worth $6,234,000 after buying an additional 396,850 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.